Amgen reports 'major' response in phase 2 trial of Aranesp for myelodysplastic syndromes

New York, June 5 - Amgen Inc. announced that after 27/28 weeks of treatment with Aranesp (darbepoetin alfa) administered every three weeks, patients with low-risk myelodysplastic syndromes who had not previously received an erythropoiesis-stimulating agent showed a "major" response of 59%, increased hemoglobin levels and improvements in patient-reported fatigue.

The updated interim data was presented at the annual meeting of the American Society of Clinical Oncology in Atlanta.

"These results, from one of the largest MDS [myelodysplastic syndromes] studies to date, are consistent with those observed at 13 weeks and provide evidence for the potential use of every-three-week dosing of Aranesp in MDS patients to reach target hemoglobin, reduce the need for blood transfusions and improve patient reported outcomes," Janice Gabrilove, professor of medicine, hematology and medical oncology at Mount Sinai School of Medicine, New York, and the study's lead investigator, said in a news release.

Amgen discovers human therapeutics and is based in Thousand Oaks, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.